Oxurion NV — Major Shareholding Notification 2025

Mar 27, 2025

PRESS RELEASE

Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received an amended transparency notification as follows:

Oxurion received a transparency notification on March 27, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 17, 2025, it held 134,344 shares of the then outstanding 3,638,344 shares, and therefore crossed under the threshold (5%) by virtue of the sale of voting securities.

This press release replaces the press release published on March 18, 2025.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY		Form TR-1 BE PART I	Transparency notification
1) Status of the notification
	Final
2) Issuer
Identification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name			Address (for legal entities)
	Atlas Special Opportunities II LLC			2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name			Address (for legal entities)
	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6			Part II
7) Date on which the threshold is crossed
			17/03/2025 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		ട
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
		3,638,344
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification			After the transaction
	# of voting rights			# of voting rights		% of voting rights
Holders of voting rights			Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC			134,344		3.69%

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%
The totals will be updated once you have clicked on C
	TOTAL (A & B)			# of voting rights	% of voting rights
			CALCULATE	134,344	3.69%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

	Atlas Special Opportunities II LLC is not a controlled entity.
12) In case of proxy voting for only one GM
					(DD/MM/YYYY)
Holder		will cease to hold / will hold again	0	voting rights as of
13) Additional information
	Presuant to the time anement to subscriping areement for convertible borns dated 3 March 2025. Allas Steating and shares in Quinn Whet by Alas Special Opportunities LLC, resulting in a shareholding of 314,390 shares (= 8.64%, denominator = 3,638,344),
	On 26 February 2025 (with settenent date on 4 March 2000) (p63 shares in Ourino NV, as a result of which its stransming decessed to 202,70 shares = 7.7%,
denominator = 3,638,344).	On 5 March 2025 (with settener date on 7 March 201 stares in our of the new of which its stareboling decreased o 2007 stares ( 7.2%,
denominator = 3,638,344).	On 6 March 222 (will settement date on 10 March 200 2,74 stares n Oxinon N. ; s a result which is strease to 27 ; 96 stare = 7.9%,
denominator = 3,638,344).	On 7 March 2025 (with settener cate on 1 March 2025), Alas Special Open NY, as a result of which its stressel to 220, for shares ( o 22%,
denominator = 3,638,344).	On 10 March 2025 (with settlement date on 12 March 11, 1994 4,899 stars in Onion N. as result of whith its stares of 18,273 shares = 5.0%,
denominator = 3,638,344).	On 13 March 2025 (vilt settement date on 17 March 229 Stares in Chinn N. as result of which is stressed of 3,244 stares (1,044 stare) = 3,09%
Done at New York
On		27/03/2025 (DD/MMYYYY)
Name & capacity Patrick Vance, Proxyholder			Signature	Patrick Vaire

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via th

In addition, a signed copy in PDE format should also be
transmitted.